Peptide Library / Detail
Pancragen
Half-life
Not extensively characterized in literature
Delivery
Subcutaneous or intramuscular injection
Dosage
—
Research Use Only
All products listed are for laboratory research only — not for human consumption. By browsing, you acknowledge these terms.
Purchase
Description
Pancragen is a synthetic tetrapeptide with the sequence Lys-Glu-Asp-Trp (KEDW) designed to support pancreatic function and glucose metabolism. Originally developed as part of peptide bioregulator research, it acts as a tissue-specific regulator of pancreatic cell differentiation and function. Studies have primarily focused on its potential to correct age-related metabolic decline and impaired glucose tolerance.
Usage
Research protocols in animal models have utilized various dosing regimens, typically administered via injection over periods ranging from several weeks to months. Studies in elderly rhesus monkeys employed regular administration to assess effects on pancreatic endocrine function and glucose metabolism. Specific human dosing protocols have not been extensively published in peer-reviewed literature.
Mechanism of Action
Pancragen functions as a tissue-specific peptide bioregulator that stimulates differentiation and functional activity of pancreatic cells, particularly during aging. The tetrapeptide acts at the cellular level to promote gene expression related to pancreatic function, enhance insulin secretion, and support beta-cell activity. Research indicates it modulates capillary permeability and cellular adhesion processes relevant to diabetic complications.
Benefits(7)
- Corrects impaired glucose tolerance in aged subjects
- Improves pancreatic endocrine function during aging
- Stimulates differentiation of pancreatic cells
- Reduces blood glucose levels in diabetic models
- Decreases capillary permeability in diabetes
- Supports functional activity of pancreatic beta cells
- May help correct age-related metabolic disorders
Side Effects(4)
- Limited published data on adverse effects in humans
- Animal studies have not reported significant toxicity
- Long-term safety profile not extensively characterized
- Potential injection site reactions with subcutaneous administration